Skip to main content

Advertisement

Fig. 2 | Cell & Bioscience

Fig. 2

From: Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors

Fig. 2

HQP1351 induces cell cycle arrest and apoptosis. a GIST 430 cells were treated with vehicle, imatinib, ponatinib or HQP1351 at 0.3 μM for 24 h, and then stained with PI for cell cycle analysis. b GIST 430 cells were treated with vehicle, imatinib, ponatinib or HQP1351 at 0.3 μM for 48 h, and then stained with Annexin V-FITC and PI for apoptosis analysis. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, n = 3

Back to article page